



Spring Group Meeting

San Francisco Specials

APRIL 30 - MAY 2, 2026



Radiation Oncology Committee

Radiation Oncology Committee

Leadership

Chair: Chul Ha, MD
 Vice-Chair: Lisa Kachnic, MD
 Executive Officer: Lisa Kachnic, MD
 Statisticians: Sam Callis, MS

Designates

AI Subcommittee Chair: T.J. FitzGerald, MD
 Breast Committee Liaison: Reshma Jagsi, MD, DPhil
 Transplant & Cell Therapies Committee Liaison: Austin Sim, MD
 Cancer Care Delivery Committee Liaison: Eileen Connolly, MD
 Prevention, Screening & Surveillance Liaison: Eileen Connolly, MD
 CNS Working Group Liaison: Tony Wang, MD
 Gastrointestinal Committee Liaison: David Horowitz, MD
 Genitourinary Committee Liaison: James Yu, MD
 Immunotherapeutics Committee Liaison: Robert Samstein, MD, PhD
 Leukemia Committee Liaison: Austin Sim, MD
 Lung Committee Liaison: Henry Park, MD
 Lymphoma Committee Liaison: Nick Figura, MD
 Melanoma Committee Liaison: Evan Wuthrick, MD
 Myeloma Committee Liaison: Chelsea Pinnix, MD, PhD
 Sarcoma Working Group Liaison: Jeremy Harris, MD
 Symptom Management & Survivorship Liaison: Erin Gillespie, MD, MPH
 Theranostics Subcommittee Chair Jeffrey Wong, MD
 Theranostics Subcommittee Vice-Chairs: Jeremie Calais MD, PhD
 Tanya Dorff, MD
 Data Coordinator: Larry Kaye
 Protocol Project Manager: Kali Nicks

Time/Location

Thursday, April 30, 2026 3:00 p.m. - 5:00 p.m.
 Room: Seacliff AB (Bay Level)

Agenda

3:00 - 3:05 pm Welcome - Chul S. Ha, MD
 3:05 - 3:10 pm Report from Executive Officer - Lisa Kachnic, MD
 3:10 - 3:15 pm Update from IROC - TJ FitzGerald, MD
 3:15 - 3:20 pm Update from NCI - Jacek Capala, PhD, DSc
 3:20 - 3:40 pm Phase 3 trial of ARPI+ADT vs. ARPI+SBRT+¹⁷⁷Lu in mHSPC - Adeel Kaiser, MD

3:40 - 4:00 pm SLOW ROLL: Salvage radiation Or Watchful waiting, Reimaging up On elevated Labs with delayed salvage - Martin Ma, MD, PhD
 4:00 - 4:20 pm NEO-ROBOT (NEOadjuvant immunotherapy with Regional nodes Or Bladder Only radiation in Trimodality therapy for NOMIBC) and Ai-ROBOT (Adjuvant immunotherapy with Regional nodes Or Bladder Only radiation in Trimodality therapy for N+ MIBC) for muscle invasive bladder cancer - Sameer Jhavar, MD
 4:20 - 4:40 pm Dosimetry guided ¹⁷⁷Lu-PSMA-617 treatment vs SOC ¹⁷⁷Lu-PSMA-617 treatment for mCRPC - Ravi Patel, MD, PhD
 4:40 - 5:00 pm Phase III randomized study testing non-inferiority of shorter-course radiation versus standard fractionation for high-risk, resectable sarcoma (S2505) - Jeremy Harris, MD
 5:00 pm Closing Remarks - Chul S. Ha, MD

Publications

The publication papers listed below from 2025 and 2026 have not appeared in previous Group Meeting publications listings. Accepted and submitted manuscripts are also listed, with the journal names withheld to honor journal embargo policies. Conference abstracts are not included.

Published/Accepted Manuscripts

Incorporating Intensity Modulated Total Body Irradiation (IMRT-TBI) Into Future Cooperative Group Clinical Trials: An NRG Hematologic Malignancies Working Group–Led Report From the National Clinical Trials Network. Nataliya Kovalchuk, Eric A. Simiele, Michael LaRiviere, Susan M. Hiniker, Michael Soike, Chunhui Han, Jeffrey Wong, Savita Dandapani, Kiran Kumar, David Parsons, Jose R. Teruel, Naamit K. Gerber, Bingqi Guo, Sheen Cherian, Tze Y. Lim, Kujtim Latifi, Nicholas B. Figura, Deepak K. Shrestha, John Grecula, Austin J. Sim, Rakesh R. Parikh, Andrea C. Lo, Koren Smith, John P. Plastaras, Ying Xiao, Bradford S. Hoppe, Sarah A. Milgrom. International Journal of Radiation Oncology, Biology, Physics 2026 Feb 17:50360-3016(26)00388-3. doi: 10.1016/j.ijrobp.2026.02.201. Online ahead of print. <https://pubmed.ncbi.nlm.nih.gov/41713515/>

Radiation Oncology Committee

Submitted Manuscripts

Consensus Radiation Therapy Organ at Risk Constraints for NCTN Trials in Hematologic Malignancies. AJ Sim, BS Hoppe, LK Ballas, SA Milgrom, SA Terezakis, CS Ha, NB Figura, RR Parikh, JC Grecula, JP Plataras, A Lo, J Ryckman, S Flampouri, CC Pinnix, CR Kelsey. Consensus Radiation Therapy Organ at Risk Constraints for NCTN Trials in Hematologic Malignancies. Under review, 2025.

